FOLH1 and neoplasm: However, the detection rate (focal uptake interpreted as tumor) of the best currently available PET tracer (PSMA) is limited at low PSA levels, indicating the relevance of the derived assessment tool for adjuvant needs (i.e., PSA level below 0.2 ng/mL: detection rate in meta-analysis 0.4 [25]).